Aarti Drugs
NSE: AARTIDRUGSBSE: 524348
₹ 447.50▲ 45.25 (+11.25%)28 Oct, 03:29 pm IST
- Market cap
- ₹ 3,442 Cr.
- P/E
- 21.2x
- P/B
- 2.24x
- 52-week range
- 318.95 – 534
- ROE
- 13%
- ROCE
- 12%
- Dividend yield
- 0.5%
- Debt / equity
- 0.37
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Aarti Drugs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)21.2 against a typical 34.3: cheaper than most peers (1st = cheapest).69th of 220
- Sales growth+19% against a typical +15.6% from a year earlier.85th of 197
- Profit growth−7.4% against a typical +18.9% from a year earlier.107th of 160
- Share price, 3 months+8.8% against a typical −0.5%.64th of 200
- Size₹ 3,442.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).62nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by 2 agenciesAA-
DefaultRiskyModerateSafeVery safe
- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA- | Stable | 24 Mar 2026 |
| CRISIL | Crisil AA- | Stable | 28 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 24 Mar 2026 | Reaffirmed | [ICRA]AA- | — | ICRA | ₹ 1,452.8 Cr. | |
| 28 Jan 2026 | Reaffirmed | Crisil AA- | — | CRISIL | ₹ 1,768 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 27 Aug 2026 | Other business matters | To consider 'Aarti Drugs Limited Performance Stock Option Plan 2026 , |
| 31 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 15 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 3 Feb 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2025 and Interim dividend for FY 2025-26, if any |
| 7 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 18 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating Profit | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 12% | 12% | 14% | 12% | 11% | 11% | 14% | 13% | 13% | 9% | 13% | 14% |
| Other Income | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | −1 |
| Interest | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 30% | 29% | 26% | 24% | 24% | 27% | 12% | −6% | 25% | −40% | 21% | 28% |
| Net Profit | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS in Rs | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.5 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- 8%
- 5 Years
- 4%
- 3 Years
- −2%
- TTM
- 11%
Compounded Profit Growth
- 10 Years
- 11%
- 5 Years
- −7%
- 3 Years
- 5%
- TTM
- 2%
Stock Price CAGR
- 10 Years
- 13%
- 5 Years
- −8%
- 3 Years
- −10%
- TTM
- —
Return on Equity
- 10 Years
- 18%
- 5 Years
- 15%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 21.2xEPS (12 months) ₹ 21.11Median P/E 17.7x
P/E (times)EPS (₹)
Prices are delayed and for information only. Nothing on this page is investment advice.